AQUA Heart, Inc., founded in Santa Ana, California, is a pioneering MedTech company dedicated to advancing cardiovascular care. The company's core mission is to improve the lives of patients with atrial fibrillation (AF) by developing innovative solutions for Pulmonary Vein Isolation (PVI) therapy. AQUA Heart aims to democratize AF therapy by providing a faster, safer, and more efficient system for PVI procedures, positioning itself at the forefront of medical innovation in this critical area.
Notable affiliated individuals include a team of world-class experts in cardiovascular medicine and technology. AQUA Heart has garnered recognition as a top innovator in the MedTech field, underscoring its significant impact on AF treatment. The company's state-of-the-art single-shot PVI therapy has the potential to transform how atrial fibrillation is managed, offering substantial improvements in patient outcomes and procedural efficiency.
